Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival
Elena Riccitelli1, Paola Giussani, Clara Di Vito
1Department of Medical Biotechnology and Translational Medicine, University of Milan, LITA-Segrate, Milan, Italy.
Abstract:
Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance mechanisms limit benefits. Recent studies support that glioblastoma stem-like cells (GSCs), a cell subpopulation within the tumour, are involved in the aberrant expansion and therapy resistance properties of glioblastomas, through still unclear mechanisms. Emerging evidence suggests that sphingosine-1-phosphate (S1P) a potent onco-promoter able to act as extracellular signal, favours malignant and chemoresistance properties in GSCs. Notwithstanding, the origin of S1P in the GSC environment remains unknown. We investigated S1P metabolism, release, and role in cell survival properties of GSCs isolated from either U87-MG cell line or a primary culture of human glioblastoma. We show that both GSC models, grown as neurospheres and expressing GSC markers, are resistant to temozolomide, despite not expressing the DNA repair protein MGMT, a major contributor to temozolomide-resistance. Pulse experiments with labelled sphingosine revealed that both GSC types are able to rapidly phosphorylate the long-chain base, and that the newly produced S1P is efficiently degraded. Of relevance, we found that S1P was present in GSC extracellular medium, its level being significantly higher than in U87-MG cells, and that the extracellular/intracellular ratio of S1P was about ten-fold higher in GSCs. The activity of sphingosine kinases was undetectable in GSC media, suggesting that mechanisms of S1P transport to the extracellular environment are constitutive in GSCs. In addition we found that an inhibitor of S1P biosynthesis made GSCs sensitive to temozolomide (TMZ), and that exogenous S1P reverted this effect, thus involving extracellular S1P as a GSC survival signal in TMZ resistance. Altogether our data implicate for the first time GSCs as a pivotal source of extracellular S1P, which might act as an autocrine/paracrine signal contributing to their malignant properties.
Insights
Glioblastoma stem-like cells (GSCs) produce extracellular sphingosine-1-phosphate (S1P), promoting their survival and resistance to temozolomide (TMZ). Inhibiting S1P biosynthesis sensitizes GSCs to TMZ, highlighting S1P
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Molecular Signaling
Background:
- Glioblastomas are aggressive brain tumors with limited treatment efficacy.
- Glioblastoma stem-like cells (GSCs) contribute to tumor progression and therapy resistance.
- Sphingosine-1-phosphate (S1P) is implicated in promoting malignancy and chemoresistance in GSCs.
Purpose of the Study:
- To investigate the origin and role of S1P in GSCs.
- To determine if GSCs are a source of extracellular S1P.
- To elucidate the contribution of extracellular S1P to temozolomide (TMZ) resistance in GSCs.
Main Methods:
- Glioblastoma stem-like cells (GSCs) were isolated from U87-MG cell line and primary human glioblastoma cultures.
- Sphingosine metabolism and S1P release were analyzed using pulse labeling experiments.
- Cellular and extracellular S1P levels were quantified.
- The effect of S1P modulation on GSC sensitivity to temozolomide (TMZ) was assessed.
Main Results:
- GSC models exhibited resistance to temozolomide (TMZ) independent of MGMT expression.
- GSCs rapidly metabolized sphingosine to S1P, with high extracellular S1P levels and an elevated extracellular/intracellular ratio.
- Extracellular S1P acted as a survival signal for GSCs, and its inhibition sensitized them to TMZ, an effect reversed by exogenous S1P.
Conclusions:
- Glioblastoma stem-like cells (GSCs) are a significant source of extracellular sphingosine-1-phosphate (S1P).
- Extracellular S1P functions as an autocrine/paracrine survival signal, contributing to GSC malignancy and temozolomide (TMZ) resistance.
- Targeting S1P metabolism or signaling represents a potential therapeutic strategy for glioblastoma.

